City

Clinical trials near Hefei, China

Active studies with a listed research site in Hefei, China.

35active studies

16recruiting now

13countries represented

201largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowPhase 1

Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity

Drug Drug Interaction (DDI), Pharmacokinetics and PharmacodynamicsCondition

UBT251, Metformin hydrochlorideTreatment

China1 locations

The United Bio-Technology (Hengqin) Co., Ltd.Sponsor

Updated 2026-08-25 · NCT07785934See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Obesity, OverweightCondition

Enicepatide, PlaceboTreatment

China18 locations

Hoffmann-La RocheSponsor

Updated 2026-08-13 · NCT07670416See eligibility →

Recruiting nowPhase 3

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes MellitusCondition

Elecoglipron, SemaglutideTreatment

Argentina, Australia201 locations

AstraZenecaSponsor

Updated 2026-07-14 · NCT07662213See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects

Healthy SubjectsCondition

HEC-007 injection, PlaceboTreatment

China1 locations

Sunshine Lake Pharma Co., Ltd.Sponsor

Updated 2026-04-27 · NCT07102251See eligibility →

Recruiting nowPhase 1

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

Overweight Subject, Healthy SubjectsCondition

Metformin, EmpagliflozinTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-01-09 · NCT07331389See eligibility →

Recruiting nowNot applicable

Effect of Vitamin D on Cardiovascular Metabolic Risk in Overweight/Obesity Adolescents in China

Cardiometabolic Risk FactorsCondition

Dietary Supplement: Vitamin D3, Dietary Supplement: Vitamin D3 placeboTreatment

China2 locations

Anhui Medical UniversitySponsor

Updated 2025-11-17 · NCT07053657See eligibility →

Recruiting nowPhase 1

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

Obesity, OverweightCondition

HRS-5817 Injection, HRS-5817 Injection PlaceboTreatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2025-11-17 · NCT06934408See eligibility →

Recruiting nowPhase 1

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

Overweight or ObesityCondition

HRS-9531 TabletTreatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2025-11-17 · NCT07150962See eligibility →

Opening soonPhase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Obesity, OverweightCondition

Berobenatide, PlaceboTreatment

China33 locations

PfizerSponsor

Updated 2026-09-04 · NCT07792954See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

China13 locations

Eli Lilly and CompanySponsor

Updated 2026-08-27 · NCT07790861See eligibility →

Opening soonPhase 2, Phase 3

Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)

Metabolic Dysfunction-Associated Steatohepatitis, Hepatic SteatosisCondition

Mazdutide, Placebo (Normal Saline)Treatment

China3 locations

West China HospitalSponsor

Updated 2026-07-21 · NCT07718126See eligibility →

Opening soonPhase 1

A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants

ObesityCondition

HS-20136-2, PlaceboTreatment

China1 locations

Jiangsu Hansoh Pharmaceutical Co., Ltd.Sponsor

Updated 2026-07-21 · NCT07716241See eligibility →

Opening soonPhase 4

AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

Obesity, Diabetes Mellitus, Type 2Condition

AI-Assisted Intensive Lifestyle Intervention, TirzepatideTreatment

China2 locations

The First Affiliated Hospital of Anhui Medical UniversitySponsor

Updated 2026-07-13 · NCT07697391See eligibility →

Opening soonPhase 2

GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial

Intracerebral HemorrhageCondition

Semaglutide, 0.5 mg/mLTreatment

China, Hong Kong3 locations

Chinese University of Hong KongSponsor

Updated 2026-05-29 · NCT07613437See eligibility →

Opening soonPhase 1

Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

Overweight, ObesityCondition

Acetaminophen, MetforminTreatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-03-30 · NCT07502001See eligibility →

Opening soonPhase 3

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）

Overweight or ObesityCondition

MDR-001, PlaceboTreatment

China45 locations

MindRank AI LtdSponsor

Updated 2025-12-22 · NCT07274137See eligibility →

Opening soonPhase 3

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

Acute Ischemic Stroke, Large Vessel OcclusionCondition

Semaglutide 0.5 mg, Standard medical treatmentTreatment

China1 locations

Wei HuSponsor

Updated 2025-01-23 · NCT06788626See eligibility →

Opening soonPhase 3

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

ObesityCondition

TQF3510 (Semaglutide Injection), Wegovy®Treatment

China66 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2024-12-18 · NCT06738979See eligibility →

Opening soonPhase 2

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

Obesity, Overweight and ObesityCondition

MDR-001, PlaceboTreatment

China19 locations

MindRank AI LtdSponsor

Updated 2024-09-24 · NCT06606483See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Brazil, China138 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT05869903See eligibility →

Active, not recruitingPhase 2

A Study of CS060380 Tablets in Patients With MASH and Obesity

Metabolic Dysfunction-associated Steatohepatitis (MASH), ObesityCondition

semaglutide, CS060380Treatment

China12 locations

Cascade Pharmaceuticals, IncSponsor

Updated 2026-08-10 · NCT07466017See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingPhase 2, Phase 3

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Obesity and OverweightCondition

Phase IIb：Efsubaglutide Alfa 5 mg QW, Phase IIb：Efsubaglutide Alfa 10 mg QWTreatment

China41 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-01-30 · NCT06921486See eligibility →

Active, not recruitingPhase 1

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

Overweight or ObesityCondition

IBI3032, placeboTreatment

China1 locations

Innovent Biologics Technology Limited (Shanghai R&D Center)Sponsor

Updated 2025-12-31 · NCT07170319See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Hefei, China

Current studies

Related cities